HC Wainwright Has Negative Outlook of Evotec FY2024 Earnings

Evotec SE (NASDAQ:EVO - Free Report) - Equities researchers at HC Wainwright cut their FY2024 earnings estimates for Evotec in a report issued on Thursday, November 7th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.51) per share for the year, down from their previous estimate of ($0.42). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Evotec's Q4 2024 earnings at ($0.04) EPS, FY2026 earnings at $0.23 EPS and FY2027 earnings at $0.47 EPS.

A number of other analysts have also recently commented on the stock. Jefferies Financial Group cut shares of Evotec from a "buy" rating to a "hold" rating and cut their price target for the company from $8.70 to $3.80 in a research report on Monday, October 7th. Morgan Stanley cut shares of Evotec from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $15.00 to $6.00 in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Evotec from a "hold" rating to a "sell" rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $5.93.

Evotec Price Performance

NASDAQ EVO traded up $0.74 on Monday, reaching $4.87. The company had a trading volume of 573,040 shares, compared to its average volume of 118,265. Evotec has a fifty-two week low of $2.85 and a fifty-two week high of $12.00. The business has a 50 day moving average of $3.54 and a two-hundred day moving average of $4.20. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.73 and a current ratio of 2.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of EVO. Vanguard Personalized Indexing Management LLC bought a new position in Evotec in the 2nd quarter valued at $87,000. Cetera Advisors LLC bought a new stake in shares of Evotec during the 1st quarter worth $188,000. Clear Harbor Asset Management LLC purchased a new position in Evotec in the 3rd quarter worth $104,000. DCF Advisers LLC raised its position in Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after purchasing an additional 67,156 shares during the period. Finally, Mediolanum International Funds Ltd purchased a new position in Evotec in the 3rd quarter worth $512,000. 5.81% of the stock is owned by institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.